Multi-ancestry transcriptome-wide association studies of cognitive function, white matter hyperintensity, and Alzheimer's disease

- 3
- Chaar, Dima L.¹, Li, Zheng², Shang, Lulu³, Ratliff, Scott M.¹, Mosley, Thomas H.^{1,4},
 Kardia, Sharon L.R.¹, Zhao, Wei^{1,5}, Zhou, X.², Smith, J.A.^{1,5}
- 7 8
- ⁹ ¹ Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor,
- 10 Michigan, United States of America
- ² Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor,
- 12 Michigan, United States of America
- ³ Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas,
- 14 United States of America
- ⁴ Memory Impairment and Neurodegenerative Dementia (MIND) Center, University of
- 16 Mississippi Medical Center, Jackson, Mississippi
- ⁵ Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor,
- 18 Michigan, United States of America
- 19
- 20
- 21
- 22
- 23 24
- 24 25
- 25 26
- 20 27
- 28
- 29
- 30
- 31
- 32
- 33 34
- 35
- 36 *Corresponding author:
- 37
- 38 Jennifer A. Smith, PhD, MPH
- 39 Department of Epidemiology
- 40 University of Michigan
- 41 1415 Washington Heights, #2631
- 42 Ann Arbor, MI 48109-2029
- 43 Phone: 734-615-9455
- 44 Fax: 734-764-3192
- 45 Email: smjenn@umich.edu
- 46 ORCID: 0000-0002- 3575-5468
- 47

48 Author Summary

49 Transcriptome-wide association studies (TWAS) can be used to understand the mechanisms of 50 gene expression that underly disease etiology. However, to date, TWAS methods have mostly 51 been used in a single ancestry group, especially European ancestry (EA), and few TWAS have 52 focused on cognitive function or structural brain measures. We used a newly developed TWAS 53 method called the Multi-ancEstry TRanscriptOme-wide analysis (METRO) to incorproate gene 54 expression data from 801 EA and 1,032 African ancestry (AA) adults to identify genes 55 associated with general cognitive function, structural brain changes called white matter 56 hyperintensities (WMH) that predispose people to vascular dementia, and another form of 57 dementia called Alzheimer's disease (AD). We found that reduced gene expression of *ICA1L* 58 was associated with more WMH and with AD, indicating its potential contribution to 59 overlapping AD and vascular dementia neuropathologies. To our knowledge, our study is the 60 first TWAS of cognitive function and neurocognitive disorders using multiple ancestries. This 61 work may expand the benefits of TWAS studies beyond a single ancestry group and help to 62 identify gene targets for pharmaceutical or preventative treatment for dementia. 63

6566 Abstract

67

67 68	Genetic variants increase the risk of neurocognitive disorders in later life including
69	Vascular Dementia (VaD) and Alzheimer's disease (AD), but the precise relationships between
70	genetic risk factors and underlying disease etiology are not well understood. Transcriptome-wide
71	association studies (TWAS) can be leveraged to better characterize the genes and biological
72	pathways underlying genetic influences on disease. To date, almost all existing TWAS have been
73	conducted using expression studies from individuals of a single genetic ancestry, primarily
74	European. Using the joint likelihood-based inference framework in Multi-ancEstry
75	TRanscriptOme-wide analysis (METRO), we leveraged gene expression data from European
76	(EA) and African ancestries (AA) to identify genes associated with general cognitive function,
77	white matter hyperintensity (WMH), and AD. Regions were fine-mapped using Fine-mapping Of
78	CaUsal gene Sets (FOCUS). We identified 266, 23, 69, and 2 genes associated with general
79	cognitive function, WMH, AD (using EA GWAS summary statistics), and AD (using AA
80	GWAS), respectively (Bonferroni-corrected alpha= $P<2.9 \times 10^{-6}$), some of which were previously
81	identified. Enrichment analysis showed that many of the identified genes were in pathways
82	related to innate immunity, vascular dysfunction, and neuroinflammation. Further,
83	downregulation of ICA1L was associated with higher WMH and with AD, indicating its potential
84	contribution to overlapping AD and VaD neuropathology. To our knowledge, our study is the
85	first TWAS of cognitive function and neurocognitive disorders that used expression mapping
86	studies in multiple ancestries. This work may expand the benefits of TWAS studies beyond a
87	single ancestry group and help to identify gene targets for pharmaceutical or preventative
88	treatment for dementia.

91 Introduction

92

93 Adult-onset dementia is comprised of a group of aging-related neurocognitive disorders 94 caused by the gradual degeneration of neurons and the loss of brain function. These changes lead 95 to a decline in cognitive abilities and impairment of daily activities and independent function. In 96 the United States, Alzheimer's disease (AD), the most common cause of dementia, affects 6.8 97 million adults age 65 and older (1). The second most common form of dementia is vascular 98 dementia (VaD), which often co-occurs with AD and is underdiagnosed (1,2). VaD is often 99 difficult to distinguish from AD because these diseases share cognitive symptoms including 100 noticeable impairment in episodic and semantic memory. While AD and VaD often co-occur, 101 each form of dementia has differing pathophysiology that may precede the illness decades prior. 102 AD is characterized by aggregation of amyloid-beta protein and neurofibrillary tangles in 103 brain tissue (3,4), while VaD may be caused by reduced blood flow to the brain as a result of 104 small vessel disease (SVD) or stroke and is commonly seen in people with hypertension (5). AD 105 is diagnosed based on a battery of memory tests, brain-imaging tests for degeneration of brain 106 cells and laboratory tests to assess the presence of amyloid and tau proteins in cerebrospinal fluid 107 (6). SVD is primarily detected on magnetic resonance imaging (MRI) as white matter 108 hyperintensities (WMH). It has been hypothesized that vascular and neurodegenerative changes 109 in the brain may interact in ways that increase the likelihood of cognitive impairment. A further 110 challenge in the field is distinguishing between individuals who are aging normally from those 111 with dementia pathology.

A greater understanding of the pathological processes that influence cognitive function in older adults is critical for early intervention during the long preclinical or prodromal phase prior to dementia onset, especially in vulnerable populations (7,8). For example, individuals of African

115 ancestry (AA) have a greater burden of and risk for developing dementia compared to Non-116 Hispanic Whites (9–12). Differences in gene expression, which are influenced by both genetic 117 and non-genetic factors, likely play a role in shaping racial/ethnic health disparities in 118 neurological outcomes. However, the underlying molecular and environmental mechanisms that 119 influence gene expression are not fully understood, especially in populations with non-European 120 ancestries. Given the multifactorial and complex nature of dementia, multi-omic data integration 121 across ancestry groups may lend insight into these disparities, allowing the identification of 122 targets for intervention and treatment in populations that are most at risk (13). 123 Genome-wide association studies (GWAS) have identified genetic variants associated 124 with cognitive function and dementia; however, most GWAS variants are located in non-coding 125 regions so their functional consequences are difficult to characterize (14). Transcriptome-wide 126 association studies (TWAS) utilize gene expression and genetic data to increase power for 127 identifying gene-trait associations and characterizing transcriptomic mechanisms underlying 128 complex diseases. To date, however, few TWAS have been conducted on cognitive or structural 129 brain measures. Further, previous TWAS have primarily been conducted in populations of 130 European ancestry (EA), but these results cannot always be generalized to other genetic 131 ancestries due to differences in allele frequencies, patterns of linkage disequilibrium (LD), and 132 relationships between SNPs and gene expression between populations (15-18). To better identify 133 gene-trait associations in non-EA ancestries, it is necessary to incorporate results from recent 134 expression quantitative trait locus (eQTL) mapping studies, which identify genetic variants that 135 explain variations in gene expression levels, conducted in different ancestry groups.(19) 136 Multi-ancEstry TRanscriptOme-wide analysis (METRO)(20) is a TWAS method that 137 uses a joint likelihood-based inference framework to borrow complementary information across

138	multiple ancestries to increase TWAS power. In this study, we used genotype and gene
139	expression data from 1,032 AA and 801 EA from the Genetic Epidemiology Network of
140	Arteriopathy (GENOA) and summary statistics from published GWAS (21-24) to identify genes
141	associated with general cognitive function, white matter hyperintensity, and AD. We then
142	examined the contribution of different ancestry-dependent transcriptomic profiles on the gene-
143	trait associations. Greater knowledge of the underlying molecular mechanisms of dementia that
144	are generalizable to both EA and AA is a critical step in evaluating potential causal variants and
145	genes that could be targeted for pharmaceutical development.
146	
147	
148	2. Materials and Methods
149	
150	2.1. Sample
151	The Genetic Epidemiology Network of Arteriopathy (GENOA)
152	The GENOA study is a community-based longitudinal study aimed at examining the
153	genetic effects of hypertension and related target organ damage (25). EA and AA hypertensive
154	sibships were recruited if at least 2 siblings were clinically diagnosed with hypertension before
155	age 60. All other siblings were invited to participate, regardless of their hypertension status.
156	Exclusion criteria included secondary hypertension, alcoholism or drug abuse, pregnancy,
157	insulin-dependent diabetes mellitus, active malignancy, or serum creatinine levels >2.5mg/dL. In
158	Phase I (1996-2001), 1,854 AA participants (Jackson, MS) and 1,583 EA participants
159	(Rochester, MN) were recruited (25). In Phase II (2000-2004), 1,482 AA and 1,239 EA
160	participants were successfully followed up, and their potential target organ damage from
161	hypertension was measured. Demographics, medical history, clinical characteristics, information
162	on medication use, and blood samples were collected in each phase. After data cleaning and

quality control, a total of 1,032 AA and 801 EA with genotype and gene expression data were
available for analysis. Written informed consent was obtained from all participants, and approval
was granted by participating institutional review boards (University of Michigan, University of
Mississippi Medical Center, and Mayo Clinic).

167

168 **2.2.** *Measures*

169 **2.2.1. Genetic Data**

170 AA and EA blood samples were genotyped using the Affymetrix® Genome-Wide 171 Human SNP Array 6.0 or the Illumina 1M Duo. We followed the procedures outlined by Shang 172 et al.(18) for data processing. For each platform, samples and SNPs with a call rate <95%, 173 samples with mismatched sex, and duplicate samples were excluded. After removing outliers 174 identified from genetic principal component analysis, there were 1,599 AA and 1,464 EA with 175 available genotype data. Imputation was performed using the Segmented HAPlotype Estimation 176 & Imputation Tool (SHAPEIT) v.2.r(26) and IMPUTE v.2(27) using the 1000 Genomes project 177 phase I integrated variant set release (v.3) in NCBI build 37 (hg19) coordinates (released in 178 March 2012). Imputation for each genotyping platform was performed separately and then 179 combined. The final set of genotype data included 30,022,375 and 26,079,446 genetic variants 180 for AA and EA, respectively. After removing genetic variants with MAF ≤ 0.01 , imputation 181 quality score (INFO score) ≤ 0.4 in any platform-based imputation, and indels, a total of 182 13,793,193 SNPs in AA and 7,727,215 SNPs in EA were available for analysis. We used the 183 GENESIS package(28) in R to infer population structure in the analytic sample, and the PC-AiR 184 function was used to extract the first five genotype PCs which were subsequently used to adjust 185 for population structure.

186 2.2.2. Gene Expression Data

187	Gene expression levels were measured from Epstein-Barr virus (EBV) transformed B-
188	lymphoblastoid cell lines (LCLs) created from blood samples from a subset of GENOA AA
189	(n=1,233) and EA (n=919). Gene expression levels of AA samples were measured using the
190	Affymetrix Human Transcriptome Array 2.0, while gene expression levels of EA samples were
191	measured using Affymetrix Human Exon 1.0 ST Array. We followed the procedures outlined by
192	Shang et al.(18) In particular, the Affymetrix Expression Console was used for quality control
193	and all array images passed visual inspection. In AA, 28 samples were removed due to either low
194	signal-to-noise ratio (n=1), abnormal polyadenylated RNA spike-in controls (Lys < Phe < Thr <
195	Dap; n=24), sample mislabeling (n=2), or low RNA integrity (n=1), resulting in a total of
196	n=1,205 AA samples for analysis. In EA, duplicated samples (n=31), control samples (n=11) and
197	sex mismatch samples (n=2) were removed, resulting in n=875 EA samples for analysis. We
198	processed data in each population separately. Raw intensity data were processed using the
199	Affymetrix Power Tool software (29). AffymetrixCEL files were normalized using the Robust
200	Multichip Average (RMA) algorithm which included background correction, quantile
201	normalization, log ₂ -transformation, and probe set summarization.(30) The algorithm also
202	includes GC correction (GCCN), signal space transformation (SST), and gain lock (value=0.75)
203	to maintain linearity. The Brainarray custom CDF(31) v.19 was used to map the probes to genes.
204	This custom CDF uses updated genomic annotations and multiple filtering steps to ensure that
205	the probes used are specific for the intended gene cluster. Specifically, it removes probes with
206	non-unique matching cDNA/EST sequences that can be assigned to more than one gene cluster.
207	As a result, gene expression data processed using custom CDF are expected to be largely free of
208	mappability issues. After mapping, ComBat(32) was used to remove batch effects. For each

209	gene, we applied a linear regression model to adjust for age, sex, and first five genotype principal
210	components (PCs). We then extracted the residuals and quantile normalized residuals across all
211	samples. We analyzed a common set of 17,238 protein coding genes that were annotated in
212	GENCODE (release 12) (33).
213	
214	2.2.3. GWAS summary statistics
215	We used summary statistics from GWAS for general cognitive function (21), WMH (22),
216	AD in EA(23), and AD in AA(24) as input for METRO. Three of the GWASs, Davies et al.
217	(2018), Sargurupremraj et al. (2020), and Bellenguez et al. (2022), were selected because they
218	are the largest meta-analyses to date with publicly available summary statistics; however, we
219	note that all three were conducted in primarily EA samples. We also selected the Kunkle et al.
220	(2021) GWAS because it is the largest meta-analysis to date with public available summary
221	statistics in primarily AA samples. Below, we describe each GWAS and also provide
222	information about the corresponding TWAS analyses that were reported in two of the input
223	GWAS (WMH(22) and AD in EA(23)) which use the same GWAS summary statistics as our
224	analysis but different gene expression data.
225	
226	General cognitive function
227	We obtained GWAS summary statistics for general cognitive function from a meta-
228	analysis by Davies et al. (2018) that includes the Cohorts for Heart and Aging Research in
229	Genomic Epidemiology (CHARGE), the Cognitive Genomics Consortium (COGENT) consortia
230	and the UK Biobank (UKB; Table 1) (21). This study included 300,486 EA individuals with ages

between 16 and 102 years from 57 population-based cohorts. This is the largest available GWAS

232	for general cognitive function, and there are currently no large-scale GWAS studies available in
233	non-EA. General cognitive function was constructed from a number of cognitive tasks. Each
234	cohort was required to have tasks that tested at least three different cognitive domains. Principal
235	component (PC) analysis was performed on the cognitive tests scores within each cohort, and the
236	first unrotated component was extracted as the measure of general cognitive function. Models
237	performed within each cohort were adjusted for age, sex, and population stratification. Exclusion
238	criteria included clinical stroke (including self-reported stroke) or prevalent dementia.
239	
240	White matter hyperintensity
241	We obtained the GWAS summary statistics for WMH from a meta-analysis conducted by
242	Sargurupremraj et al. (2020) that included 48,454 EA and 2,516 AA with mean age of 66.0
243	(SD=7.5) years from 23 population-based studies from the CHARGE consortium and UKB
244	(Table 1) (22). We obtained publicly available GWAS summary statistics from only EA
245	individuals. Summary statistics for only EA are publicly available for this GWAS. WMH was
246	measured from MRI scans obtained from scanners with field strengths ranging from 1.5 to 3.0
247	Tesla and interpreted using a standardized protocol blinded to clinical or demographic features.
248	In addition to T1 and T2 weighted scans, some cohorts included fluid-attenuated inversion
249	recovery (FLAIR) and/or proton density (PD) sequences to measure WMH from cerebrospinal
250	fluid. WMH volume measures were inverse normal transformed, and models adjusted for sex,
251	age, genetic PCs and intracranial volume (ICV). Exclusion criteria included history of stroke or
252	other pathologies that influence measurement of WMH at the time of MRI.
253	To functionally characterize and prioritize individual WMH genomic risk loci,
254	Sargurupremraj et al.(22) (2020) conducted TWAS using TWAS-Fusion(34) with summary

255	statistics from the WMH SNP-main effects (EA only) analysis and weights from gene expression
256	reference panels from blood (Netherlands Twin Registry; Young Finns Study), arterial
257	(Genotype-Tissue Expression, GTEx), brain (GTEx, CommonMind Consortium) and peripheral
258	nerve tissue (GTEx). This study did not perform fine-mapping following TWAS analysis.
259	
260	Alzheimer's disease (GWAS in EA)
261	We obtained the EA GWAS summary statistics for Alzheimer's disease from stage I
262	meta-analysis by Bellenguez et al. (2022) that included EA from the European Alzheimer and
263	Dementia Biobank (EADB), GR@ACE, EADI, GERAD/PERADES, DemGene, Bonn, the
264	Rotterdam study, CCHS study, NxC and the UKB (Table 1) (23). The meta-analysis was
265	performed on 39,106 clinically diagnosed AD cases, 46,828 proxy-AD and related dementia
266	(ADD) cases, and 401,577 controls. AD cases were clinically diagnosed in all cohorts except
267	UKB, where individuals were identified as proxy-ADD cases if their parents had dementia.
268	Participants without the clinical diagnosis of AD, or those without any family history of
269	dementia, were used as controls. Models performed within each cohort were adjusted for PCs
270	and genotyping centers, when necessary.
271	To examine the downstream effects of new AD-associated variants on molecular
272	phenotypes in various AD-relevant tissues, Bellenguez et al. (2022) conducted a TWAS with
273	stage I AD GWAS results. The TWAS was performed by training functional expression and
274	splicing reference panels based on the Accelerating Medicines Partnership (AMP)-AD bulk brain
275	and EADB lymphoblastoid cell lines (LCL) cohorts, while leveraging pre-calculated reference
276	panel weights(35) for the GTEx dataset(36) in tissues and cells of interest. TWAS associations
277	were then fine-mapped using Fine-mapping Of CaUsal gene Sets (FOCUS) (37).

278

279 Alzheimer's disease (GWAS in AA)

280	We also acquired the AA GWAS summary statistics for Alzheimer's disease from meta-
281	analysis by Kunkle et al. (2021)(24) that included individuals of African American ancestry from
282	15 cohort studies from the AD Genetics Consortium (ADGC; Table 1). The meta-analysis was
283	performed on 2,748 clinically diagnosed AD cases and 5,222 controls with a mean age of 74.2
284	years (SD=13.6). Models performed within each cohort were adjusted for age, sex, and PCs for
285	population substructure.
286	
287	2.3 Statistical Methods
288	2.3.1. Multi-ancestry transcriptome-wide association study
289	Using the Multi-ancEstry TRanscriptOme-wide analysis (METRO) (20), we conducted a
290	high-powered TWAS with calibrated type I error control to identify the key gene-trait
291	associations and transcriptomic mechanisms underlying general cognitive function, WMH and
292	AD. Since gene expression prediction models constructed in different ancestries may contain
293	complementary information, even when the input GWAS was conducted in a single ancestry
294	(20), we used METRO to model gene expression from EA and AA simultaneously. METRO
295	uses a joint-likelihood framework that accounts for SNP effect size heterogeneity and LD
296	differences across ancestries. The framework selectively upweights information from the
297	ancestry that has greater certainty in the gene expression prediction model, increasing power and
298	allowing characterization of the relative contribution of each ancestry to the TWAS results.
299	METRO is described in Li et al.(20) Briefly, each gene is examined separately using gene
300	expression data from M different genetic ancestries. Z_m is the n_m -vector of gene expression

301	measurements on n_m individuals in the m^{th} ancestry with $m \in \{1,, M\}$. For the gene of interest,
302	all cis -SNPs (p) , which are in potential linkage disequilibrium (LD) with each other, were
303	extracted as predictors for gene expression. G_m is denoted as the $n_m x p$ genotype matrix for these
304	cis-SNPs. Besides the gene expression data, we also used GWAS summary statistics from n
305	individuals for an outcome trait of interest. γ is the <i>n</i> -vector of outcome measurements in the
306	GWAS data and G is the corresponding $n \times p$ genotype matrix on the same set of p cis-SNPs.
307	The expression vector z_m , the outcome vector γ and each column of the genotype matrixes are
308	centered and standardized. G_m and G have a mean of zero and variance of one. For each TWAS,
309	we used GWAS summary statistics in the form of marginal z-scores and a SNP-SNP correlation
310	(LD) matrix estimated with genotype data from our GENOA sample that correspond with the
311	ancestry of the GWAS (EA or AA). The following equations describe the relationships between
312	the SNPs, gene expression and the outcome:

 $\boldsymbol{z}_m = \boldsymbol{G}_m \boldsymbol{\beta}_m + \boldsymbol{\epsilon}_m, \qquad (\text{Equation 1})$

313
$$\boldsymbol{\gamma} = \alpha(\boldsymbol{G}\boldsymbol{\beta}) + \boldsymbol{\epsilon}_{\gamma},$$
 (Equation 2)

314 Equation (1) describes the relationship between gene expression and the *cis*-SNP genotypes in the gene expression study in GENOA for the m^{th} ancestry (EA or AA). β_m is a p 315 vector of the *cis*-SNP effects on the gene expression in the m^{th} ancestry and \mathcal{E}_m is an n_m -vector of 316 residual errors with each element following an independent and normal distribution N(0, σ_m^2) 317 with an ancestry specific variance σ_m^2 . Equation (2) describes the relationship between the 318 319 genetically regulated gene expression (GReX), calculated from estimated SNP prediction 320 weights, and the outcome trait (general cognitive function, WMH or AD) from the GWAS. There, $G\beta$ denotes an *n*-vector of GReX constructed for the GWAS individuals, where $\beta = \Sigma_m$ 321

322 $w_m\beta_m$ is a *p*-vector of SNP effects on the gene expression in the GWAS data, where the weights 323 $\Sigma_{m=1}^{M} w_m = 1$ and $w_m \ge 0$. The alpha value (α) is the effect of GReX constructed for the GWAS 324 individuals on the outcome trait, and ε_v is an n_m -vector of residual errors with each element 325 following an independent and normal distribution N(0, σ_m^2). Both equations, specified based on 326 separate studies, are connected through the predictive SNP effects on the gene expression (β_m) 327 and β). A key assumption made is that the SNP effects on the gene expression in the GWAS, β , 328 can be expressed as a weighted summation of the SNP effects on gene expression in the 329 expression studies conducted across ancestries. 330 We derived the overall GReX effect α and the contribution weight of each ancestry (w₁) 331 for AA and w_2 for EA) to infer the extent and contribution of the two genetic ancestries in 332 informing the GReX-trait association. The joint model defined in Equations 1 and 2 allows us to 333 borrow association strength across multiple ancestries to enable powerful inference of GReX-334 trait associations for general cognitive function, WMH and AD. We declared the gene to be 335 significant if the p-value was below the corresponding Bonferroni corrected threshold for the number of tested genes ($P < 0.05/17,238 = 2.90 \times 10^{-6}$). Manhattan plots and quantile-quantile (QQ) 336 337 plots were generated using the qqman(38) R package. 338

339 **2.3.2 Fine-mapping analysis**

Since genes residing in the same genomic region may share eQTLs or contain eQTL
SNPs in LD with each other, TWAS test statistics for genes in the same region can be highly
correlated, making it difficult to identify the true biologically relevant genes among them. To
prioritize the putatively causal genes identified by METRO for general cognitive function,
WMH, and AD, we conducted TWAS fine-mapping using FOCUS (Fine-mapping Of CaUsal

345	gene Sets) (37). To identify a genomic region with at least one significant gene detected by
346	METRO, we obtained a set of independent, non-overlapping genomic regions, or LD blocks,
347	using Ldetect (39). In each analyzed genomic block, using a standard Bayesian approach, we
348	assigned a posterior inclusion probability (PIP) for each gene to be causal, given the observed
349	TWAS statistics. We used gene-level Z scores, created from p-values using the inverse
350	cumulative distribution function (CDF) of a standard normal distribution, as input into FOCUS.
351	We then ranked the PIPs and computed the 90%-credible set that contains the causal gene with
352	90% probability. In the FOCUS analysis, a null model which assumes none of the genes in the
353	region are causally associated with the trait is also considered as a possible outcome and may be
354	included in the credible set. Through fine-mapping, we narrowed down significantly associated
355	genes identified by METRO to a shorter list of putatively true associations.

356

357 **2.3.3 Characterization of identified genes**

358 To interpret our TWAS findings, both before and after fine-mapping, we further 359 examined whether the genes identified by METRO overlapped with those previously identified 360 by their corresponding input GWAS. We created a set of Venn diagrams of overlapping genes 361 identified using METRO with those from the SNP-based GWAS association results(21–24) 362 mapped to the nearest gene using the VennDiagram R package (40). We then constructed a 363 second set of Venn diagrams showing overlapping genes identified using METRO with genes 364 identified by gene-based association analyses in each of the input GWAS studies. The gene-365 based analyses were conducted using MAGMA(41) (general cognitive function,(21) WMH(22), 366 and AD (AA GWAS)(24)) or gene prioritization tests (AD (EA GWAS)(23)). Finally, we 367 created a set of Venn diagrams comparing genes identified using METRO with those identified

in the TWAS that were conducted as part of the WMH(22) and AD (EA GWAS)(23) input
GWAS studies. We used the *geneSynonym* R package(42) to ensure that genes named differently
across studies were captured.

371

372 2.3.4 Functional Enrichment Analysis

373 To characterize the biological function of the identified genes by METRO for general 374 cognitive function, WMH and AD, we performed gene set enrichment analysis. Specifically, we 375 used the g:GOSt(43) tool on the web software g:Profiler and mapped the genes to known 376 functional informational sources, including Gene Ontology (GO): molecular function (MF), GO: 377 biological process (BP), GO: cellular component (CC), Kyoto Encyclopedia of Genes and 378 Genomes (KEGG), Reactome (REAC), WikiPathways (WP), Transfac (TF), MiRTarBase 379 (MIRNA), Human Protein Atlas (HPA), CORUM protein complexes, and Human Phenotype 380 Ontology (HP). In this analysis, we used the default option g:SCS method (Set Counts and Sizes) 381 in g:Profiler for multiple testing correction and presented pathways identified with an adjusted p-382 value < 0.05. Driver terms in GO are highlighted using a two-stage algorithm for filtering GO 383 enrichment results, providing a more efficient and reliable approach compared to traditional 384 clustering methods. This feature groups significant terms into sub-ontologies based on their 385 relations, and the second stage identifies leading gene sets that give rise to other significant 386 functions in the same group of terms. This method uses a greedy search strategy that recalculates 387 hypergeometric p-values and results in the consideration of multiple leading terms in a 388 component, rather than selection of terms with the highest significance level.

389

390 Results

391	In Table 1, we provide descriptive statistics for the samples used in the eQTL mapping
392	study (e.g., 1,032 AA and 801 EA from GENOA) and the four input GWAS.(21-23) The
393	GENOA eQTL study included participants with a mean age of 56.9 (SD=10.0) years. More than
394	half of participants were female (65.6%). Mean age of participants was 56.9 (SD=7.8) years in
395	the general cognitive function GWAS(21), and 64.2 years in the WMH GWAS.(22) In the AD
396	GWAS in EA (23), mean age was 73.6 (SD=8.1) years for cases and 67.9 (SD=8.6) years for
397	controls. In the AD GWAS in AA (24), mean age was 74.2 (SD=13.6) years for all participants.
398	Using METRO, we identified 602 genes associated with general cognitive function, 45
399	genes associated with WMH, 231 genes associated with AD (EA GWAS), and 9 genes
400	associated with AD (AA GWAS) that were significant at the Bonferroni corrected alpha level
401	(P<2.90x10 ⁻⁶ ; Figure 1, Tables S1-3). Genomic inflation factors for the TWAS p-values ranged
402	from 1.00 to 2.55 (Figure 2). Among the three neurocognitive outcomes, prior to fine-mapping,
403	METRO TWAS identified the ICA1L gene overlapping between WMH and AD (from EA
404	GWAS); the FMNL1 gene overlapping between WMH and general cognitive function; and 22
405	genes enriched in AD-related pathways and functions overlapping between general cognitive
406	function and AD (from EA GWAs) (Figure 3a; Figure S1). After fine-mapping, the only
407	overlapping gene that remained was ICA1L between WMH and AD (Figure 3b). The METRO
408	TWAS for AD (AA GWAS) identified 9 genes overlapping with those identified in AD (EA
409	GWAS); however, following fine-mapping, only TOMM40 overlapped between the two AD
410	TWASs (Figure 3b).
411	For all identified genes, we also examined the contribution weights of expression
412	prediction models for the EA and AA ancestries, prior to fine-mapping ($P < 2.90 \times 10^{-6}$; Figure 4).

413 For the WMH TWAS, we found that a large proportion of genes had stronger contributions from

EA weights than AA weights (65.2%). This is consistent with Li et al. (2022)(20) who found that
the gene expression prediction models constructed in the same ancestry as the input GWAS, in
this case EA, often have larger contribution weights than those constructed in other ancestries.
However, for both general cognitive function and AD (EA and AA GWAS), the contributions
from EA and AA weights were similar, which likely increased power to identify genes relevant
to AA.

420 After fine-mapping, there were 266 genes in the 90%-credible set across 172 different 421 genomic regions for general cognitive function. This gene set included 82 genes that were not 422 previously identified in the SNP-based GWAS results (mapped to the nearest gene) or the gene-423 based analysis results from Davies et al. (2018)(21) (Figure 5, Table S1); however, it is likely 424 that some of these genes are in broader genomic regions tagged by the GWAS-identified SNPs. 425 Specifically, there were 126 and 168 overlapping genes between METRO and the SNP-based 426 and gene-based associations from Davies et al. (2018)(21), respectively (Figure 5). The 266 427 METRO-identified genes were enriched in regulatory pathways involved in protein binding (p_{adi} = 1.17 x 10⁻⁵), developmental cell growth (p_{adj} = 3.33 x 10⁻⁵), and protein metabolic process (p_{adj} 428 = 7.18 x 10⁻⁴), as well as neurodevelopmental processes such as neuron to neuron synapse (p_{adi} = 429 1.22×10^{-3}) and neuron projection ($p_{adi} = 7.14 \times 10^{-3}$; Figure 6). The 82 genes that were not 430 431 previously identified in Davies et al. (2018)(21) were enriched for positive regulation of biological process ($p_{adj} = 1.77 \times 10^{-2}$), proteasome activator complex ($p_{adj} = 1.00 \times 10^{-2}$), 432 nucleoplasm ($p_{adj} = 1.29 \times 10^{-2}$) and chromatin ($p_{adj} = 4.71 \times 10^{-5}$; Figure S2). 433 434 After fine-mapping, there were 23 genes in the 90%-credible set across 15 genomic 435 regions for WMH, including 12 genes that were not previously identified in the SNP-based

436 GWAS results mapped to the nearest gene or the gene-based analysis results from

437 Sargurupremraj et al. (2020)(22) (Figure 7, Table S2). Specifically, there were 7 and 12 438 overlapping genes between METRO and the SNP-based and gene-based associations from 439 Sargurupremraj et al. (2020)(22), respectively (Figure 7). The 23 METRO-identified genes were enriched for zinc finger motif ($p_{adj} = 1.27 \times 10^{-2}$), miRNA has-212-5p ($p_{adj} = 1.94 \times 10^{-2}$) and 440 retinal inner plexiform layer ($p_{adi} = 3.86 \times 10^{-2}$; Figure 8). The 12 genes associated with WMH 441 442 that were previously not identified by Sargurupremraj et al. (2020)(22) were enriched for DNA binding domain Zinc Finger Protein 690 (ZNF690; $p_{adi} = 2.52 \times 10^{-3}$) and ClpX protein 443 degradation complex ($p_{adi} = 4.97 \times 10^{-2}$; Figure S3). 444

445 After fine-mapping, there were 69 genes in the 90%-credible set across 56 genomic 446 regions associated with AD (EA GWAS), including 45 genes that were not previously identified 447 in the SNP-based GWAS results mapped to the nearest gene or the gene prioritization analysis 448 results from Bellenguez et al. (2022)(23) (Figure 9, Table S3). Specifically, there were 16 and 14 449 overlapping genes between METRO and the SNP-based and gene prioritization test results from 450 Bellenguez et al. (2022)(23), respectively (Figure 9). The 69 METRO-identified genes were 451 enriched for AD-associated processes including regulation of amyloid fibril formation ($p_{adi} =$ 1.87 x 10⁻³), amyloid-beta clearance ($p_{adj} = 1.90 \times 10^{-3}$), microglial cell activation ($p_{adj} = 5.79 \times 10^{-3}$) 452 10^{-3}), amyloid-beta metabolic process ($p_{adi} = 1.07 \times 10^{-2}$), and neurofibrillary tangle ($p_{adi} = 2.80 \times 10^{-2}$) 453 454 10^{-4} ; Figure 10). The 45 genes associated with AD that were previously not identified by Bellenguez et al. (2022)(23) were enriched for hematopoietic cell lineage ($p_{adj} = 1.73 \times 10^{-3}$) and 455 neurofibrillary tangle ($p_{adj} = 9.13 \times 10^{-3}$; Figure S4). 456

We identified 2 genes, *APOE* and *PVRL2*, in the 90%-credible set associated with AD
(AA GWAS) (Table S4). After fine-mapping, none of these genes overlapped with SNP-based
GWAS results mapped to the nearest gene or the gene-based analysis results from Kunkle et al.

460	(2021), since they are both in the broader APOE region, which was the only identified gene in
461	Kunkle et al (2021). The 2 METRO-identified genes were enriched for coreceptor-mediated
462	virion attachment to host ($p_{adj} = 4.96 \times 10^{-2}$; Figure 11).
463	We compared the genes identified by METRO before and after fine-mapping with those
464	identified by TWAS studies in Sargurupremraj et al. (2020)(22) and Bellenguez et al. (2022)(23)
465	which used TWAS-Fusion (Figure 12). For WMH, there were 16 and 10 genes identified both by
466	METRO before and after fine-mapping and by the TWAS-Fusion analysis conducted by
467	Sargurupremraj et al. (2020)(22), respectively (Table 2). For AD, there were 24 and 10 genes
468	identified both by METRO before and after fine-mapping and by the TWAS-Fusion followed by
469	FOCUS fine-mapping analysis conducted by Bellenguez et al. (2022)(23) (Table 3). ICA1L was
470	the only gene overlapping between all four AD and WMH TWAS association results.
471	
471 472	Discussion
	Discussion While previous studies have identified genes associated with cognitive function, WMH,
472	
472 473	While previous studies have identified genes associated with cognitive function, WMH,
472 473 474	While previous studies have identified genes associated with cognitive function, WMH, and AD, there are few TWAS that utilize genetic and gene expression data from multiple
472 473 474 475	While previous studies have identified genes associated with cognitive function, WMH, and AD, there are few TWAS that utilize genetic and gene expression data from multiple ancestries to elucidate gene-trait associations and molecular mechanisms underlying the
472 473 474 475 476	While previous studies have identified genes associated with cognitive function, WMH, and AD, there are few TWAS that utilize genetic and gene expression data from multiple ancestries to elucidate gene-trait associations and molecular mechanisms underlying the etiologies of cognitive function and neurocognitive disorders. Using the METRO method in
 472 473 474 475 476 477 	While previous studies have identified genes associated with cognitive function, WMH, and AD, there are few TWAS that utilize genetic and gene expression data from multiple ancestries to elucidate gene-trait associations and molecular mechanisms underlying the etiologies of cognitive function and neurocognitive disorders. Using the METRO method in GWAS consisting primarily of EA followed by FOCUS fine-mapping, we identified 266, 23, and
 472 473 474 475 476 477 478 	While previous studies have identified genes associated with cognitive function, WMH, and AD, there are few TWAS that utilize genetic and gene expression data from multiple ancestries to elucidate gene-trait associations and molecular mechanisms underlying the etiologies of cognitive function and neurocognitive disorders. Using the METRO method in GWAS consisting primarily of EA followed by FOCUS fine-mapping, we identified 266, 23, and 69 genes associated with general cognitive function, WMH, and AD, respectively, with 82, 12

482 dementia using both EA and AA expression data may enhance our understanding of cognitive

health prior to and following the onset of dementia and further allow us to generalize findingsfrom large scale EA GWAS to other ancestries.

485	AD and SVD have overlapping features that contribute to dementia neuropathology
486	including breakdown of the blood-brain barrier(44) and the presence of small cortical and
487	subcortical infarcts, microbleeds, perivascular spacing, and WMH in brain tissue(45). After fine-
488	mapping, Islet Cell Autoantigen 1 Like (ICA1L) was identified in both the WMH and AD
489	TWAS. This is as a highly plausible prioritized gene that is likely to modulate the metabolism of
490	amyloid precursor protein (APP)(23) and increase risk of AD. ICA1L encodes a protein whose
491	expression is activated by type IV collagen and plays a crucial role in myelination(46). Increased
492	ICA1L expression is also associated with lower risk of AD(47-49) and small vessel strokes
493	(SVS), the acute outcomes of cerebral SVD, which may lead to VaD(50). Consistent with these
494	studies, our TWAS found that decreased expression of ICA1L is associated with increased risk of
495	AD and WMH, a subclinical indicator of SVD. Single-cell RNA-sequencing has shown ICA1L
496	expression to be enriched in cortical glutamatergic excitatory neurons, which are crucial
497	components in neural development and neuropathology through their role in cell proliferation,
498	differentiation, survival, neural network formation and cell death(51,52). ICA1L has been
499	examined as a possible drug target for SVD, AD, and other neurodegenerative diseases(50,53);
500	however, it is not recommended as a prioritized drug at this time due to potential side effects
501	including increased risk of coronary artery disease and myocardial infarction as well as lower
502	diastolic blood pressure(53). Nevertheless, ICA1L may contribute to overlapping AD and VaD
503	neuropathology, and it could be a potential target for therapeutics and/or preventative treatments
504	for AD and VaD in the future if adverse events can be reduced.

505	Our TWAS of AD (from EA GWAS) identified 45 genes that were not identified in the
506	SNP-based GWAS results mapped to the nearest gene or the gene-based analysis reported in
507	Bellenguez et al. (2022)(23). The 45 genes were enriched for hematopoietic cell lineage, which
508	are progenitors of red and white blood cells including those related to immunity (e.g., natural
509	killer cells, T- and B- lymphocytes and other types of leukocytes)(54-60). Our TWAS identified
510	genes that have been previously associated with AD, including APOE, TOMM40, APOC4, CLU,
511	PICALM and CR2, among others(23,61,62). While we identified APOE, the strongest genetic
512	risk factor for AD in most populations, after fine-mapping, we did not identify ABCA7 which
513	confers an equal or even greater risk for AD in AA(63-65). This finding is perhaps not
514	surprising considering that our TWAS was conducted using an EA GWAS, and the strength of
515	association between ABCA7 and AD is comparatively weaker in EA than in AA.(65) To identify
516	genes associated with AD risk in AA populations, specifically, it would be beneficial to perform
517	a TWAS utilizing a well-powered AD GWAS in AA.
518	Our TWAS of AD (from AA GWAS) (24) identified only TOMM40 and PVRL2, both
519	proximal to APOE. TOMM40 was also identified in our TWAS of AD (from EA GWAS), as
520	well as other AD GWAS (23,61,62). PVRL2 has been associated with metabolic syndrome,
521	diabetic dyslipidemia, and AD(66,67). One study found that polymorphisms in PVRL2 interact
522	with variants in TOMM40 to increase AD risk through pathways related to amyloid-beta
523	metabolism in older Chinese adults(67). As larger AD GWAS in AA become available, we may
524	be able to identify additional genes associated with disease while leveraging transcriptomic data
525	from EA and AA.
526	In our AD EA TWAS, we also identified genes associated with other neurological and

527 autoimmune diseases including Parkinson's disease (CYB561(68) and SLC25A39(69)), Crohn's

528	disease (ATG16L1(70)), Amyotrophic lateral sclerosis (SIGLEC9(71)), and Riboflavin Transport
529	Deficiency (SLC52A1(72)). These diseases have in common the progressive peripheral and
530	cranial degeneration of neurons that impact processes such as voluntary muscle movement,
531	vision, hearing and sensation. Although not explicitly identified in Bellenguez et al. (2022)(23),
532	we also identified genes that were associated with AD in other studies including RIN3 that is
533	implicated in tau-mediated pathology, the MS4A (4A and 6A) locus associated with mast cell
534	activation, TP53INP1 and ZYX that have been linked to myeloid enhancer activity(73), and
535	APOC4, which is located proximal to APOE(74). We also identified additional genes involved in
536	B cell autoimmunity (HLA-DQA2(75,76) and CSTF1(77)), neurodegenerative processes
537	(SUPT4H1(78), C6orf10(79), IKZF1(80), and DEDD(81)), and neuronal growth (IKZF1(80) and
538	STYX(82)). Our findings support the hypothesis that chronic activation of immune cells resident
539	in the brain and peripheral nervous system appear to play a critical role in neuroinflammatory
540	responses that drive the progression of neurodegeneration in AD.(83) Further, consistent with
541	findings that AD and VaD often co-exist, our AD TWAS identified genes that were associated
542	with lacunar and ischemic strokes as well as cerebral small vessel disease in other studies,
543	including SLC39A13(84), RAPSN(84), MAF1(85), and MME(86,87).
544	Although our WMH TWAS identified 12 genes that were not included in the SNP-based
545	GWAS results mapped to the nearest gene or the gene-based analysis reported in Sargurupremraj
546	et al. (2020)(22), other studies found associations between MAP1LC3B(88), ARMS2(89,90) and
547	HTRA1(84) with ischemic stroke, lacunar stroke, and cerebral SVD. The WMH TWAS also
548	identified genes associated with AD (ARMS2)(91), atrial fibrillation (NEURL(92) and
549	GJC1(93)), innate immunity (EFTUD2(94)) and apoptosis and neurodevelopment (PDCD7(95),

FBXO31(96), and *ClpX*(97)). The 12 unique genes identified for WMH were enriched for DNA

551 binding domain Zinc Finger Protein 690(98), which plays an essential role in gene regulation, 552 transcription and various cellular processes, and ClpX protein degradation complex(99), which 553 maintains protein homeostasis. Our findings were consistent with studies that showed 554 neuroinflammation to be an immunological cascade reaction by glial cells of the central nervous 555 system where innate immunity resides. 556 While our TWAS for general cognitive function did not show overlapping genes between 557 the TWAS for AD and VaD, we identified genes associated with general cognitive function that 558 were not explicitly identified by Davies et al. (2018)(21) which were associated with pre-clinical 559 AD and VaD risk factors including cardiovascular diseases, immunity and Alzheimer's 560 neuropathology. Our TWAS also identified genes previously associated with cognitive domains, 561 neuropathology, and psychiatric illness including reading-related skills and neural structures (SEMA6D(100) and SETBP1(101)), working memory tasks (CDH13(102)) and Schizophrenia 562 563 (HP(103,104), C18orf1(105) and TMEM180(106)). There are likely also distinct transcriptomic 564 mechanisms that differentiate cognitive function and normal age-related brain changes from 565 pathways related to dementia. Individuals who never develop dementia or significant cognitive 566 decline still experience brain deterioration in normal aging that includes gray and white matter 567 loss and ventricular enlargement which is accompanied by memory decline(107). Further, 568 previous GWAS for general cognitive function and AD have shown few overlapping 569 loci(21,108). In addition, studies of older individuals who are cognitively "resilient" with intact 570 cognitive function, despite the presence of AD neuropathology, have found the genetic 571 architecture of cognitive resilience to be distinct from that of AD(109). As such, relatively little 572 is known about the pathways underlying cognitive aging in those without dementia. Thus,

studying transcriptomic mechanisms that affect general cognitive function before development of
dementia may shed light on cognitive aging without dementia.

575 We also compared genes identified by METRO after fine-mapping with those identified 576 by TWAS-Fusion in Sargurupremraj et al. (2020)(22) and Bellenguez et al. (2022)(23). Among 577 the 92 genes associated with WMH in Sargurupremraj et al. (2020)(22) and 23 genes identified 578 by METRO, 10 genes overlapped. We note that the Sargurupremraj et al. (2020)(22) did not 579 perform fine-mapping of their TWAS results, which is likely why we identified substantially 580 fewer genes. There were also 10 overlapping genes among the 66 genes associated with AD in 581 Bellenguez et al. (2022)(23) and 69 genes identified by METRO. For both TWAS comparisons, 582 a relatively small number of genes overlap likely due to differences in eQTL prediction 583 modeling. Sargurupremraj et al. (2020)(22) and Bellenguez et al. (2022)(23) used eQTL data 584 from brain tissue, while we used eOTL data from transformed beta lymphocytes in blood tissue. 585 While brain tissue is more relevant to WMH and AD phenotypes, blood cells do touch every cell 586 bed that affects the brain, and are related to chronic inflammation, immunity, and oxidative 587 stress, which are linked to cognitive performance and dementia. TWAS results from blood tissue 588 in multiple ancestries provide complementary information to those reported in the GWAS. 589 Several limitations in the present study should be noted. First, our gene expression levels 590 were measured using transformed B-lymphocytes from immortalized cell lines in GENOA. 591 While transformed B-lymphocytes are a convenient source of DNA from blood tissue, we lack 592 eQTL data for tissues that may be most relevant for AD and WMH (e.g., brain tissue, small brain 593 vessels, and microglia). However, B-lymphocytes provide a unique and efficient way to examine 594 the functional effects of genetic variations on gene expression that minimizes environmental 595 influences(110). Second, METRO follows the standard TWAS approach of analyzing one gene

596 at a time. Since genes residing in the same genomic region may share eQTLs or contain eQTL 597 SNPs that are in LD with each other, the TWAS test statistics of genes in the same region may be 598 highly correlated. To that end, it may be challenging to identify the truly biologically relevant 599 genes among them(37,111). As such, we paired METRO with FOCUS to allow us to narrow 600 down the list of potential causal genes for AD, VaD, and cognitive decline(37,112). Lastly, we 601 primarily utilized EA GWAS that were publicly available with large sample sizes for general 602 cognitive function, WMH, and AD. As expected, the gene expression prediction models 603 constructed in the same ancestry as the GWAS (EA) tended to have larger contribution weights 604 than AA. While we conducted a TWAS of AD in AA, the sample size of the AA GWAS likely 605 did not allow us to properly power our TWAS. As such, a future direction would be to conduct 606 TWAS of these traits using summary statistics from well-powered GWAS with AA ancestry or 607 multiple ancestries as they become available. 608 Our study also has notable strengths. To our knowledge, our study is the first TWAS 609 using expression mapping studies in multiple ancestries (EA and AA) to identify genes 610 associated with cognitive function and neurocognitive disorders. By leveraging the 611 complementary information in gene expression prediction models constructed in EA and AA, as 612 well as the uncertainty in SNP prediction weights, we were able to conduct a highly powered 613 TWAS to identify important gene-trait associations and transcriptomic mechanisms related to 614 innate immunity, vascular dysfunction and neuroinflammation underlying AD, VaD, and general 615 cognitive function. Using METRO, we were also able to estimate the ancestry contribution 616 weights for specific genes and identify the extent to which a gene in EA or AA may contribute to

617 the trait. However, it is noteworthy that the larger the contribution of the expression prediction

618 models in the same ancestry as the GWAS (primarily EA, in this study) may allow for better

619 predictive performance in the same ancestry. We also conducted FOCUS fine-mapping to 620 narrow in on a list of putatively causal genes among multiple significant genes in a region. Our 621 results suggest that there are similar pathways that contribute to healthy cognitive aging and 622 progression of dementia, as well as distinct pathways that are unique to each neuropathology. By 623 understanding overlapping and unique genes and transcriptomic mechanisms associated with 624 each outcome, we may identify possible targets for prevention and/or treatments for cognitive 625 aging and dementia.

626

627 Conclusion

628 In the present study, we conducted a multi-ancestry TWAS in EA and AA to identify 629 genes associated with general cognitive function, WMH and AD. We identified genes associated 630 with innate immunity, vascular dysfunction, and neuroinflammation. The WMH and AD TWAS 631 also indicated that downregulation of ICA1L may contribute to overlapping AD and VaD 632 neuropathology. To our knowledge, this study is the first TWAS analysis using expression 633 mapping studies in multiple ancestries to identify genes associated with cognitive function and 634 neurocognitive disorders, which may help to identify gene targets for pharmaceutical or 635 preventative treatment for dementia.

636

- 638 Author Contributions: Conceptualization, D.L.C., J.A.S.; methodology, D.L.C., J.A.S., X.Z.;
- 639 software, formal analysis, and investigation, D.L.C., Z.L., L.S., S.M.R.; resources, T.H.M. and
- 640 S.L.R.K.; writing—original draft preparation, D.L.C., J.A.S.; writing—review and editing,
- 641 D.L.C., S.M.R., W.Z., T.H.M., S.L.R.K., X.Z., J.A.S.; visualization, D.L.C., Z.L.; supervision,
- 642 J.A.S.; funding acquisition, S.L.R.K. and J.A.S. All authors have read and agreed to the
- 643 published version of the manuscript.
- 644 **Funding**: Support for the Genetic Epidemiology Network of Arteriopathy (GENOA) was
- 645 provided by the National Heart, Lung and Blood Institute (NHLBI, U01HL054457,
- 646 RC1HL100185, R01HL087660, R01HL119443, R01HL133221) and the National Institute of
- 647 Neurological Disorders and Stroke (NINDS, R01NS041558) of the NIH.
- 648 **Informed Consent Statement:** Written informed consent was obtained from all subjects
- 649 involved in the study.
- 650 **Data Availability Statement**: The phenotype data and *APOE* genotypes used in the current
- study are available upon reasonable request to J.A.S. and S.L.R.K., and with a completed data
- use agreement (DUA). All other genotype data are available from the Database of Genotypes and
- 653 Phenotypes (dbGaP): phs001401.v2.p1. Methylation and gene expression data are available from
- the Gene Expression Omnibus (GEO): GSE210256 and GSE138914. Due to IRB restriction,
- mapping of the sample IDs between genotype data (dbGaP) and methylation data (GEO) cannot
- be provided publicly, but is available upon written request to J.A.S. and S.L.R.K.
- 657 Acknowledgments: The authors wish to thank the staff and participants of the GENOA study.
- 658 **Conflicts of Interest**: The authors declare no conflict of interest.
- 659
- 660
- 661
- 662

663

Table 1. Sample characteristics of expression quantitative trait locus (eQTL) mapping study and genome-wide association studies (GWAS) participants

eQTL mapping study: Genetic Epidemiology Network of Arteriopathy (GENOA)

	Mean (SD) or N (%) or N
N	N=1833
Age (years)	56.85 (10.0)
Female	1202 (65.6%)
Race/Ethnicity	
African Americans	1032 (56.3%)
European Americans	801 (43.7%)

General cognitive function GWAS: CHARGE, COGENT, UKB^a (Davies et al., 2018)

	Mean (SD) or N (%) or N
Ν	300,486
Age (years)	56.91 (7.8)
Female	52.20%
Excluded for dementia and/or stroke diagnosis	N=4919

White matter hyperintensity (WMH) GWAS: CHARGE and UKB^a (Sargurupremraj et al., 2020)

	Mean (SD) or N (%) or N
N	48,454
Age (years)	64.17
Female	29215 (57.6%)
WMH volume (cm ³)	7.06 (8.8)
Excluded for stroke or pathologies	N=1572

EA Alzheimer's Disease (AD) GWAS: EADB, GR@ACE, EADI, GERAD/PERADES, DemGene, Bonn, the Rotterdam study, the CCHS study, NxC and the UKB^a (Bellenguez et al., 2022)

	Mean (SD) or N (%) or N
Discovery sample	
AD cases	N=39,106
AD proxy cases	N=46,828
Controls	N=401,577
Age (years)	
AD cases or proxy cases	73.55 (8.1)
controls	67.86 (8.6)
Female	
AD cases or proxy cases	62.90%
controls	56.10%

	Mean (SD) or N (%) or N
N	7,970
AD cases	2,748 (34.5%)
controls	5,222 (65.5%)
Age (years)	74.2 (13.6)
Female	
AD cases	1,944 (69.8%)
controls	3,743 (71.7%)

Abbreviations: EA, European ancestry; AA, African ancestry

^{*a*} GWAS include only European ancestry participants.

666 ^{*b*} GWAS includes only African ancestry participants.

668

Table 2. Genes for WMH identified both by METRO followed by fine-mapping with FOCUS and by TWAS-Fusion conducted by Sargurupremraj et al. (2020)

Gene	ENSG	Chr	Start	End	Gene Name	Accession number
CALCRL	ENSG0000064989	2	188206691	188313187	calcitonin receptor like receptor	Source: HGNC Symbol; Acc: HGNC:1670
DCAKD	ENSG00000172992	17	43100706	43138499	dephospho-CoA kinase domain containing	Source: HGNC Symbol; Acc: HGNC: 2623
EFEMP1	ENSG00000115380	2	56093102	56151274	EGF containing fibulin extracellular matrix protein 1	Source: HGNC Symbol; Acc: HGNC: 3218
GJC1	ENSG00000182963	17	42875816	42908184	gap junction protein gamma 1	Source: HGNC Symbol; Acc: HGNC: 4280
ICA1L	ENSG00000163596	2	203637873	203736489	islet cell autoantigen 1 like	Source: HGNC Symbol; Acc: HGNC: 1444
KLHL24	ENSG00000114796	3	183353398	183402307	kelch like family member 24	Source: HGNC Symbol; Acc: HGNC: 2594
NBEAL1	ENSG00000144426	2	203879331	204091101	neurobeachin like 1	Source: HGNC Symbol; Acc: HGNC: 2068
NEURL	ENSG00000107954	10	105253462	105352303	neuralized E3 ubiquitin protein ligase 1	Source: HGNC Symbol; Acc: HGNC: 7761
NMT1	ENSG00000136448	17	43035360	43186384	N-myristoyltransferase 1	Source: HGNC Symbol; Acc: HGNC: 7857
WBP2	ENSG00000132471	17	73841780	73852588	WW domain binding protein 2	Source: HGNC Symbol; Acc: HGNC: 1273

669 Abbreviations: HGNC, Human Genome Organisation Gene Nomenclature Committee

Table 3. Genes for AD identified both by METRO followed by fine-mapping with FOCUS and by TWAS-Fusion followed by fine-mapping with FOCUS conducted by Bellenguez et al. (2022)


Gene	ENSG	Ch r	Start	End	Gene Name	Accession number
BLNK	ENSG00000955 85	10	97948927	98031344	B cell linker	Source:HGNC Symbol;Acc:HGNC:14211
CPSF3	ENSG000001192 03	2	9563780	9613230	cleavage and polyadenylation specific factor 3	Source:HGNC Symbol;Acc:HGNC:2326
DDX54	ENSG000001230 64	12	11359497 8	11362328 4	DEAD-box helicase 54	Source:HGNC Symbol;Acc:HGNC:20084
GRN	ENSG00000305 82	17	42422614	42430474	granulin precursor	Source:HGNC Symbol;Acc:HGNC:4601
ICA1L	ENSG000001635 96	2	20363787 3	20373648 9	islet cell autoantigen 1 like	Source:HGNC Symbol;Acc:HGNC:14442
KLF16	ENSG000001299	19	1852398	1863578	KLF transcription factor 16	Source:HGNC Symbol;Acc:HGNC:16857
LACTB	ENSG000001036 42	15	63414032	63434260	lactamase beta	Source:HGNC Symbol;Acc:HGNC:16468
PPP4C	ENSG000001499	16	30087299	30096697	protein phosphatase 4 catalytic subunit	Source:HGNC Symbol;Acc:HGNC:9319
SHARPI N	ENSG000001795 26	8	14515353 6	14516302 7	SHANK associated RH domain interactor	Source:HGNC Symbol;Acc:HGNC:25321
TBX6	ENSG000001499 22	16	30097114	30103245	T-box transcription factor 6	Source:HGNC Symbol;Acc:HGNC:11605


673

674


676 (a) General cognitive function from Davies et al. (2018) GWAS



















689 (d) Alzheimer's Disease from Kunkle et al. (2021) (AA GWAS sample)

692 Figure 1. Manhattan plots of -log₁₀ p-values for gene-trait associations in METRO.

- 693 Manhattan plots of the association between genes and (a) general cognitive function using
- 694 summary statistics from Davies et al. (2018), (b) White matter hyperintensity from
- 695 Sargurupremraj et al. (2020), (c) Alzheimer's disease from Bellenguez et al. (2022) (EA GWAS
- 696 sample) and (d) Alzheimer's disease from Kunkle et al. (2021) (AA GWAS sample) using
- 697 GENOA gene expression data. The red line indicates significance after Bonferroni correction
- 698 ($P < 2.90 \times 10^{-6}$).
- 699










Figure 2. Quantile-quantile plots of -log₁₀ p-values for gene-trait associations in METRO. Q-Q plots of the associations between genes and (a) general cognitive function (λ = 2.55) using summary statistics from Davies et al. (2018), (b) white matter hyperintensity ($\lambda = 1.45$) from Sargurupremraj et al. (2020), (c) Alzheimer's disease (λ = 2.09) from Bellenguez et al. (2022) (EA GWAS sample) and (d) Alzheimer's disease (λ = 1.0) from Kunkle et al. (2021)(AA GWAS sample) using GENOA gene expression data.



- 714 Figure 3. Venn diagrams comparing number of genes associated with general cognitive
- function, white matter hyperintensity and Alzheimer's disease (AD) in European ancestry 715
- 716 (EA) and AD in African ancestry (AA) using METRO, prior to and following FOCUS fine-717 mapping.
- 718 Venn diagrams comparing the number of genes associated with general cognitive function
- 719 (purple; N=266 genes), white matter hyperintensity (WMH; green; N=23 genes) Alzheimer's
- 720 disease (AD) in EA (orange; N=69 genes), and AD in AA (yellow; N=2 genes), (a) prior to
- 721 fine-mapping and (b) following FOCUS(5) fine-mapping using METRO and GENOA
- 722 expression data after Bonferroni correction ($P < 2.90 \times 10^{-6}$), with GWAS summary statistics
- 723 obtained from the Davies et al. (2018), Sargurupremraj et al. (2020), Bellenguez et al. (2022),
- 724 and Kunkle et al. (2021).
- 725



726 727

Figure 4. Contribution weights of expression prediction models across all significant fine mapped genes identified by METRO.


730 Barplots of general cognitive function, white matter hyperintensity and Alzheimer's disease

(AD) in European ancestry (EA) and AD in African ancestry (AA) comparing the proportion of


r32 significant genes with higher contribution weights of expression prediction models across all

significant genes ($P < 2.90 \times 10^{-6}$). Black bars are the standard errors for the estimated proportions.

- 734
- 735



- 738 Figure 5. Venn diagram comparing number of METRO-identified genes associated with
- 739 general cognitive function following FOCUS fine-mapping and genes identified by Davies
- 740 et al. (2018) gene-based and SNP-based analyses.
- 741 Venn diagram comparing the number of genes associated with general cognitive function
- obtained from METRO using GENOA gene expression data after Bonferroni correction
- 743 ($P < 2.90 \times 10^{-6}$) and FOCUS fine-mapping (red) and Davies et al. (2018). Davies et al. results
- included SNP-based association results that were mapped to the nearest gene ($P < 5 \times 10^{-8}$; yellow),
- 745 and gene-based association results ($P < 2.75 \times 10^{-6}$; blue).
- 746



ID	Term ID	Term Name	Adjusted P-value
		GO:MF	
1	GO:0005515	protein binding	1.17E-05
2	GO:0140110	Transcription regulator activity	6.23E-03
3	GO:0003677	DNA binding	2.23E-02
		GO:BP	
4	GO:0048588	developmental cell growth	3.33E-05
5	GO:0019538	Protein metabolic process	7.18E-04
6	GO:0006357	Regulation of transcription by RNA polymerase II	4.79E-03
7	GO:0051171	Regulation of nitrogen compound metabolic processes	4.79E-03
8	GO:0080090	Regulation of primary metabolic process	5.86E-03
9	GO:0061387	Regulation of extent of cell growth	1.56E-02
10	GO:0042221	Response to chemical	3.06E-02
11	GO:0050794	Regulation of cellular process	3.13E-02
12	GO:0048518	Positive regulation of biological process	3.24E-02
		GO:CC	
13	GO:0005654	nucleoplasm	8.23E-05
14	GO:0000785	chromatin	7.56E-04
15	GO:0098984	Neuron to neuron synapse	1.22E-03
16	GO:0005737	cytoplasm	1.84E-03
17	GO:0043005	neuron projection	7.14E-03
18	GO:0031967	organelle envelope	1.96E-02


750

751 Figure 6. Functional enrichment analysis on the fine-mapped gene set identified for general 752 cognitive function using METRO TWAS (N=266 genes). The top panel consists of a 753 Manhattan plot that illustrates the enrichment analysis results. The x-axis represents functional 754 terms that are grouped and color-coded by data sources, including Gene Ontology (GO): 755 molecular function (MF; red), GO: biological process (BP; orange), GO: cellular component 756 (CC; dark green), Kyoto Encyclopedia of Genes and Genomes (KEGG; pink), Reactome 757 (REAC; dark blue), WikiPathways (WP; turquoise), Transfac (TF; light blue), MiRTarBase 758 (MIRNA; emerald green), Human Protein Atlas (HPA; dark purple), CORUM protein complexes 759 (light green), and Human Phenotype Ontology (HP; violet), in order from left to right. The y-axis 760 shows the adjusted enriched $-\log_{10}$ p-values <0.05. Multiple testing correction was performed using g:SCS method (Set Counts and Sizes) that takes into account overlapping terms. The top 761 762 panel highlights driver GO terms identified using the greedy filtering algorithm in g:Profiler. The light circles represent terms that were not significant after filtering. The circle sizes are in 763 764 accordance with the corresponding term size (i.e., larger terms have larger circles). The number 765 in parentheses following the source name in the x-axis shows how many significantly enriched 766 terms were from this source.




769

770




771



774 Sargurupremraj et al. (2020) gene-based and SNP-based analyses.

- Venn diagram comparing the number of significantly associated genes associated with white
- 776 matter hyperintensity (WMH) obtained from METRO using GENOA expression data after
- Bonferroni correction ($P < 2.90 \times 10^{-6}$), and fine-mapping (red) and Sargurupremraj et al. (2020).
- 778 Sargurupremraj et al. results included SNP-based association results that were mapped to the
- nearest gene ($P < 5x10^{-8}$; yellow), and gene-based association results ($P < 2.77x10^{-6}$; blue).
- 780
- 781
- 782



783

١D	Term ID	Term Name	Adjusted P-value
		TF	
1	TF:M12713	Factor: ZNF690; motif: GTCTACRCNG	1.27E-02
		MIRNA	
2	MIRNA: has-miR-212-5p	hsa-miR-212-5p	1.94E-02
		НРА	
3	HPA:0411242	Retina; inner plexiform layer [≥Medium]	3.86E-02

784

785 Figure 8. Functional enrichment analysis on the fine-mapped gene set identified for white 786 matter hyperintensity using METRO TWAS (N=23 genes). The top panel consists of a 787 Manhattan plot that illustrates the enrichment analysis results. The x-axis represents functional 788 terms that are grouped and color-coded by data sources, including Gene Ontology (GO): 789 molecular function (MF; red), GO: biological process (BP; orange), GO: cellular component 790 (CC; dark green), Kyoto Encyclopedia of Genes and Genomes (KEGG; pink), Reactome 791 (REAC; dark blue), WikiPathways (WP; turquoise), Transfac (TF; light blue), MiRTarBase 792 (MIRNA; emerald green), Human Protein Atlas (HPA; dark purple), CORUM protein complexes 793 (light green), and Human Phenotype Ontology (HP; violet), in order from left to right. The y-axis 794 shows the adjusted enriched $-\log_{10}$ p-values < 0.05. Multiple testing correction was performed 795 using g:SCS method (Set Counts and Sizes) that takes into account overlapping terms. The top 796 panel highlights driver GO terms identified using the greedy filtering algorithm in g:Profiler. The 797 light circles represent terms that were not significant after filtering. The circle sizes are in 798 accordance with the corresponding term size (i.e., larger terms have larger circles). The number 799 in parentheses following the source name in the x-axis shows how many significantly enriched 800 terms were from this source. 801

803 Genes identified from Genes identified from Bellenguez et al. Bellenguez et al. Gene-prioritization **SNP-based** association results (N=170) results (N=83) 40 116 27 6 8 10 45 Genes associated with Alzheimer's disease obtained

Alzheimer's disease obtaine from GENOA expression data using METRO (N=69)

804

Figure 9. Venn diagram comparing number of METRO-identified genes associated with
 Alzheimer's disease (EA GWAS) following FOCUS fine-mapping and genes identified by

807 Bellenguez et al. (2022) gene prioritization and SNP-based analyses.

808 Venn diagram comparing the number of significantly associated genes associated with

809 Alzheimer's disease (from EA GWAS) obtained from METRO using GENOA expression data

after Bonferroni correction ($P < 2.90 \times 10^{-6}$) and fine-mapping (red) and Bellenguez et al. (2022).


811 Bellenguez et al. results included SNP-based association results that were mapped to the nearest

gene ($P < 5 \times 10^{-8}$; yellow), and gene prioritization results for the genes in the novel AD risk loci

813 (blue). In the gene prioritization analysis, Bellenguez et al. analyzed the downstream effects of

814 new AD-associated loci on molecular phenotypes (i.e., expression, splicing, protein expression,

- 815 methylation and histone acetylation) in various *cis*-quantitative trait loci (*cis*-QTL) catalogues
- 816 from AD-relevant tissues, cell types and brain regions.
- 817
- 818
- 819




820

ID	Term ID	Term Name	Adjusted P-value
		GO:BP	
1	GO:1905906	regulation of amyloid fibril formation	1.87E-03
2	GO:0097242	amyloid-beta clearance	1.90E-03
3	GO:0001774	microglial cell activation	5.79E-03
4	GO:0050435	amyloid-beta metabolic process	1.07E-02
5	GO:0030450	regulation of complement activation, classical pathway	2.71E-02
6	GO:0050794	regulation of cellular process	3.60E-02
		GO: CC	
7	GO:0097418	neurofibrillary tangle	2.80E-04
8	GO:0005794	Golgi apparatus	4.39E-03

821

822 Figure 10. Functional enrichment analysis on the fine-mapped gene set identified for 823 Alzheimer's disease (EA GWAS) using METRO TWAS (N=69 genes). The top panel consists 824 of a Manhattan plot that illustrates the enrichment analysis results. The x-axis represents 825 functional terms that are grouped and color-coded by data sources, including Gene Ontology 826 (GO): molecular function (MF; red), GO: biological process (BP; orange), GO: cellular 827 component (CC; dark green), Kyoto Encyclopedia of Genes and Genomes (KEGG; pink), 828 Reactome (REAC; dark blue), WikiPathways (WP; turquoise), Transfac (TF; light blue), 829 MiRTarBase (MIRNA; emerald green), Human Protein Atlas (HPA; dark purple), CORUM 830 protein complexes (light green), and Human Phenotype Ontology (HP; violet), in order from left 831 to right. The y-axis shows the adjusted enriched $-\log_{10}$ p-values < 0.05. Multiple testing 832 correction was performed using g:SCS method (Set Counts and Sizes) that takes into account 833 overlapping terms. The top panel highlights driver GO terms identified using the greedy filtering 834 algorithm in g:Profiler. The light circles represent terms that were not significant after filtering. 835 The circle sizes are in accordance with the corresponding term size (i.e., larger terms have larger 836 circles). The number in parentheses following the source name in the x-axis shows how many 837 significantly enriched terms were from this source. 838



843

844 Figure 11. Functional enrichment analysis fine-mapped gene set identified for Alzheimer's 845 disease (AA GWAS) using METRO TWAS (N=2 genes). The top panel consists of a 846 Manhattan plot that illustrates the enrichment analysis results. The x-axis represents functional 847 terms that are grouped and color-coded by data sources, including Gene Ontology (GO): 848 molecular function (MF; red), GO: biological process (BP; orange), GO: cellular component 849 (CC; dark green), Kyoto Encyclopedia of Genes and Genomes (KEGG; pink), Reactome 850 (REAC; dark blue), WikiPathways (WP; turquoise), Transfac (TF; light blue), MiRTarBase (MIRNA; emerald green), Human Protein Atlas (HPA; dark purple), CORUM protein complexes 851 (light green), and Human Phenotype Ontology (HP; violet), in order from left to right. The y-axis 852 853 shows the adjusted enriched $-\log_{10} p$ -values < 0.05. Multiple testing correction was performed 854 using g:SCS method (Set Counts and Sizes) that takes into account overlapping terms. The top 855 panel highlights driver GO terms identified using the greedy filtering algorithm in g:Profiler. The 856 light circles represent terms that were not significant after filtering. The circle sizes are in 857 accordance with the corresponding term size (i.e., larger terms have larger circles). The number 858 in parentheses following the source name in the x-axis shows how many significantly enriched 859 terms were from this source.

860

861



- 864 Figure 12. Venn diagram comparing METRO TWAS results prior to and following
- 865 FOCUS fine-mapping with TWAS results from Sargurupremraj et al. (2020) and 866 Bellenguez et al. (2022)

866 **Bellenguez et al. (2022).**

- 867 Venn diagram comparing METRO TWAS results (a) prior to and (b) following FOCUS fine-
- 868 mapping with TWAS results using Fusion for white matter hyperintensity from Sargurupremraj
- 869 et al. (2020) without fine-mapping and Alzheimer's disease from Bellenguez et al. (2022) (EA
- 870 GWAS) with FOCUS fine-mapping.
- 871
- 872

873 **References**

- 874
- 2023 Alzheimer's disease facts and figures. Alzheimer's & Dementia. 2023 Apr;19(4):1598–
 695.
- De Reuck J, Maurage CA, Deramecourt V, Pasquier F, Cordonnier C, Leys D, et al. Aging
 and cerebrovascular lesions in pure and in mixed neurodegenerative and vascular dementia
 brains: a neuropathological study. Folia Neuropathol. 2018;56(2):81–7.
- Hof PR, Glannakopoulos P, Bouras C. The neuropathological changes associated with
 normal brain aging. Histol Histopathol. 1996 Oct;11(4):1075–88.
- 4. Perl DP. Neuropathology of Alzheimer's Disease. Mt Sinai J Med. 2010;77(1):32–42.
- 5. Cohuet G, Struijker-Boudier H. Mechanisms of target organ damage caused by hypertension:
 Therapeutic potential. Pharmacology & Therapeutics. 2006 Jul 1;111(1):81–98.
- 885 6. Weller J, Budson A. Current understanding of Alzheimer's disease diagnosis and treatment.
 886 F1000Res. 2018 Jul 31;7:F1000 Faculty Rev-1161.
- 887 7. Hubbard BM, Fenton GW, Anderson JM. A quantitative histological study of early clinical
 888 and preclinical Alzheimer's disease. Neuropathol Appl Neurobiol. 1990 Apr;16(2):111–21.
- 889
 8. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):280–92.
- 893 9. Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia
 894 incidence between six racial and ethnic groups over 14 years. Alzheimers Dement. 2016
 895 Mar;12(3):216–24.
- 896 10. Barnes LL, Bennett DA. Alzheimer's disease in African Americans: risk factors and
 897 challenges for the future. Health Aff (Millwood). 2014 Apr;33(4):580–6.
- 898 11. Brewster P, Barnes L, Haan M, Johnson JK, Manly JJ, Nápoles AM, et al. Progress and
 899 future challenges in aging and diversity research in the United States. Alzheimers Dement.
 900 2019 Jul;15(7):995–1003.
- 12. Rajan KB, Weuve J, Barnes LL, Wilson RS, Evans DA. Prevalence and incidence of
 clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population
 study. Alzheimers Dement. 2019 Jan;15(1):1–7.
- 13. Cacabelos R, Torrellas C. Epigenetics of Aging and Alzheimer's Disease: Implications for
 Pharmacogenomics and Drug Response. International Journal of Molecular Sciences. 2015
 Dec;16(12):30483–543.

- 14. Tam V, Patel N, Turcotte M, Bossé Y, Paré G, Meyre D. Benefits and limitations of genomewide association studies. Nat Rev Genet. 2019 Aug;20(8):467–84.
- 15. Lappalainen T, Sammeth M, Friedländer MR, 't Hoen PA, Monlong J, Rivas MA, et al.
 Transcriptome and genome sequencing uncovers functional variation in humans. Nature.
 2013 Sep 26;501(7468):506–11.
- 912 16. Mogil LS, Andaleon A, Badalamenti A, Dickinson SP, Guo X, Rotter JI, et al. Genetic
 913 architecture of gene expression traits across diverse populations. PLOS Genetics. 2018 Aug
 914 10;14(8):e1007586.
- 915 17. Wojcik G, Graff M, Nishimura K, Tao R, Haessler J, Gignoux C, et al. Genetic analyses of
 916 diverse populations improves discovery for complex traits. Nature. 2019;570(7762):514–8.
- 917 18. Shang L, Smith JA, Zhao W, Kho M, Turner ST, Mosley TH, et al. Genetic Architecture of
 918 Gene Expression in European and African Americans: An eQTL Mapping Study in
 919 GENOA. Am J Hum Genet. 2020 Apr 2;106(4):496–512.
- 920 19. Nica AC, Dermitzakis ET. Expression quantitative trait loci: present and future. Philos Trans
 921 R Soc Lond B Biol Sci. 2013 Jun 19;368(1620):20120362.
- 20. Li Z, Zhao W, Shang L, Mosley TH, Kardia SLR, Smith JA, et al. METRO: Multi-ancestry
 transcriptome-wide association studies for powerful gene-trait association detection. The
 American Journal of Human Genetics. 2022 May 5;109(5):783–801.
- 21. Davies G, Lam M, Harris SE, Trampush JW, Luciano M, Hill WD, et al. Study of 300,486
 individuals identifies 148 independent genetic loci influencing general cognitive function.
 Nat Commun. 2018 May 29;9(1):2098.
- Sargurupremraj M, Suzuki H, Jian X, Sarnowski C, Evans TE, Bis JC, et al. Cerebral small
 vessel disease genomics and its implications across the lifespan. Nature Communications.
 2020 Dec 8;11(1):6285.
- 931 23. Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New
 932 insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet.
 933 2022 Apr 4;1–25.
- 24. Kunkle BW, Schmidt M, Klein HU, Naj AC, Hamilton-Nelson KL, Larson EB, et al. Novel
 Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the
 African Genome Resources Panel: A Meta-analysis. JAMA Neurol. 2021 Jan 1;78(1):102–
 13.
- 25. Daniels PR, Kardia SLR, Hanis CL, Brown CA, Hutchinson R, Boerwinkle E, et al. Familial
 aggregation of hypertension treatment and control in the Genetic Epidemiology Network of
 Arteriopathy (GENOA) study. Am J Med. 2004 May 15;116(10):676–81.
- 941 26. Delaneau O, Zagury JF, Marchini J. Improved whole-chromosome phasing for disease and
 942 population genetic studies. Nat Methods. 2013 Jan;10(1):5–6.

- 943 27. Howie BN, Donnelly P, Marchini J. A Flexible and Accurate Genotype Imputation Method
 944 for the Next Generation of Genome-Wide Association Studies. PLOS Genetics. 2009 Jun
 945 19;5(6):e1000529.
- 946 28. Gogarten SM, Sofer T, Chen H, Yu C, Brody JA, Thornton TA, et al. Genetic association
 947 testing using the GENESIS R/Bioconductor package. Bioinformatics. 2019;35(24):5346–8.
- 948 29. Lockstone HE. Exon array data analysis using Affymetrix power tools and R statistical
 949 software. Briefings in Bioinformatics. 2011 Nov 1;12(6):634–44.
- 30. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix
 GeneChip probe level data. Nucleic Acids Research. 2003 Feb 15;31(4):e15.
- 31. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, et al. Evolving gene/transcript
 definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Research.
 2005 Nov 1;33(20):e175.
- 32. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using
 empirical Bayes methods. Biostatistics. 2007 Jan 1;8(1):118–27.
- 33. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, et al.
 GENCODE: the reference human genome annotation for The ENCODE Project. Genome research. 2012;22(9):1760–74.
- 34. Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BWJH, et al. Integrative approaches for
 large-scale transcriptome-wide association studies. Nat Genet. 2016 Mar;48(3):245–52.
- 35. Barbeira AN, Bonazzola R, Gamazon ER, Liang Y, Park Y, Kim-Hellmuth S, et al.
 Exploiting the GTEx resources to decipher the mechanisms at GWAS loci. Genome
 Biology. 2021 Jan 26;22(1):49.
- 36. THE GTEX CONSORTIUM. The GTEx Consortium atlas of genetic regulatory effects
 across human tissues. Science. 2020 Sep 11;369(6509):1318–30.
- 37. Mancuso N, Freund MK, Johnson R, Shi H, Kichaev G, Gusev A, et al. Probabilistic fine mapping of transcriptome-wide association studies. Nature genetics. 2019;51(4):675–82.
- 38. Turner SD. qqman: an R package for visualizing GWAS results using Q-Q and manhattan
 plots [Internet]. bioRxiv; 2014 [cited 2023 Jun 6]. p. 005165. Available from:
 https://www.biorxiv.org/content/10.1101/005165v1
- 39. Berisa T, Pickrell JK. Approximately independent linkage disequilibrium blocks in human
 populations. Bioinformatics. 2016;32(2):283.
- 40. Chen H, Boutros PC. VennDiagram: a package for the generation of highly-customizable
 Venn and Euler diagrams in R. BMC Bioinformatics. 2011 Jan 26;12(1):35.

- 41. de Leeuw CA, Stringer S, Dekkers IA, Heskes T, Posthuma D. Conditional and interaction
 gene-set analysis reveals novel functional pathways for blood pressure. Nat Commun. 2018
 Sep 14;9(1):3768.
- 42. Mancarcı BO. Gene Synonym [Internet]. 2022 [cited 2023 Jul 6]. Available from:
 https://github.com/oganm/geneSynonym
- 43. Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web
 server for functional enrichment analysis and conversions of gene lists (2019 update).
 Nucleic Acids Research. 2019 Jul 2;47(W1):W191–8.
- 44. Chagnot A, Barnes SR, Montagne A. Magnetic Resonance Imaging of Blood–Brain Barrier
 permeability in Dementia. Neuroscience. 2021 Oct 15;474:14–29.
- 45. Kalaria RN, Sepulveda-Falla D. Cerebral Small Vessel Disease in Sporadic and Familial
 Alzheimer Disease. The American Journal of Pathology. 2021 Nov 1;191(11):1888–905.

46. Zhang C, Qin F, Li X, Du X, Li T. Identification of novel proteins for lacunar stroke by
integrating genome-wide association data and human brain proteomes. BMC Medicine.
2022 Jun 23;20(1):211.

- 47. Bai B, Vanderwall D, Li Y, Wang X, Poudel S, Wang H, et al. Proteomic landscape of
 Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery. Mol
 Neurodegener. 2021 Aug 12;16:55.
- 48. Wingo AP, Liu Y, Gerasimov ES, Gockley J, Logsdon BA, Duong DM, et al. Integrating
 human brain proteomes with genome-wide association data implicates new proteins in
 Alzheimer's disease pathogenesis. Nat Genet. 2021 Feb;53(2):143–6.
- 997 49. Ou YN, Yang YX, Deng YT, Zhang C, Hu H, Wu BS, et al. Identification of novel drug
 998 targets for Alzheimer's disease by integrating genetics and proteomes from brain and blood.
 999 Mol Psychiatry. 2021 Oct;26(10):6065–73.
- 50. Cullell N, Gallego-Fábrega C, Cárcel-Márquez J, Muiño E, Llucià-Carol L, Lledós M, et al.
 ICA1L Is Associated with Small Vessel Disease: A Proteome-Wide Association Study in
 Small Vessel Stroke and Intracerebral Haemorrhage. Int J Mol Sci. 2022 Mar
 15;23(6):3161.
- 1004 51. Liu DZ, Sharp FR. Excitatory and Mitogenic Signaling in Cell Death, Blood–brain Barrier
 1005 Breakdown, and BBB Repair after Intracerebral Hemorrhage. Transl Stroke Res. 2012 Jul
 1006 1;3(1):62–9.
- 1007 52. Lai TW, Zhang S, Wang YT. Excitotoxicity and stroke: Identifying novel targets for
 1008 neuroprotection. Progress in Neurobiology. 2014 Apr 1;115:157–88.
- 53. Ge YJ, Ou YN, Deng YT, Wu BS, Yang L, Zhang YR, et al. Prioritization of Drug Targets
 for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and
 Blood. Biological Psychiatry. 2023 May 1;93(9):770–9.

- 54. Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating
 viruses and cellular organisms. Nucleic Acids Research. 2021 Jan 8;49(D1):D545–51.
- 1014 55. De Bruijn MF, Speck NA. Core-binding factors in hematopoiesis and immune function.
 1015 Oncogene. 2004 May 24;23(24):4238–48.
- 1016 56. Maillard I, Adler SH, Pear WS. Notch and the Immune System. Immunity. 2003
 1017 Dec;19(6):781–91.
- 1018 57. Radtke F, Wilson A, Mancini SJC, MacDonald HR. Notch regulation of lymphocyte
 1019 development and function. Nat Immunol. 2004 Mar;5(3):247–53.
- 1020 58. Rothenberg EV, Taghon T. MOLECULAR GENETICS OF T CELL DEVELOPMENT.
 1021 Annu Rev Immunol. 2005 Apr 1;23(1):601–49.
- 1022 59. Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat Rev Immunol.
 1023 2005 Mar;5(3):230–42.
- 102460. Spits H. Development of $\alpha\beta$ T cells in the human thymus. Nat Rev Immunol. 20021025Oct;2(10):760–72.
- 1026 61. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta1027 analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.
 1028 Nat Genet. 2013 Dec;45(12):1452–8.
- 1029 62. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common
 1030 variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with
 1031 Alzheimer's disease. Nat Genet. 2011 May;43(5):429–35.
- 1032 63. Reitz C, Mayeux R. Genetics of Alzheimer's Disease in Caribbean Hispanic and African
 1033 American Populations. Biological Psychiatry. 2014 Apr;75(7):534–41.
- 1034 64. Reitz C, Jun G, Naj A, Rajbhandary R. Variants in the ATP-Binding Cassette Transporter
 1035 (ABCA7), Apolipoprotein E □4,and the Risk of Late-Onset Alzheimer Disease in African
 1036 Americans. JAMA. 2013 Apr 10;309(14):1483–92.
- 1037 65. De Roeck A, Van Broeckhoven C, Sleegers K. The role of ABCA7 in Alzheimer's disease:
 1038 evidence from genomics, transcriptomics and methylomics. Acta Neuropathol. 2019 Aug
 1039 1;138(2):201–20.
- 66. Guardiola M, Muntané G, Martínez I, Martorell L, Girona J, Ibarretxe D, et al. Metabolic
 Overlap between Alzheimer's Disease and Metabolic Syndrome Identifies the PVRL2 Gene as a New Modulator of Diabetic Dyslipidemia. Int J Mol Sci. 2023 Apr 18;24(8):7415.
- 1043 67. Liang X, Liu C, Liu K, Cong L, Wang Y, Liu R, et al. Association and interaction of
 1044 TOMM40 and PVRL2 with plasma amyloid-β and Alzheimer's disease among Chinese
 1045 older adults: a population-based study. Neurobiol Aging. 2022 May;113:143–51.

68. Chatterjee P, Roy D, Bhattacharyya M, Bandyopadhyay S. Biological networks in 1046 1047 Parkinson's disease: an insight into the epigenetic mechanisms associated with this disease. 1048 BMC Genomics. 2017 Sep 12;18(1):721. 1049 69. Gialluisi A, Reccia MG, Modugno N, Nutile T, Lombardi A, Di Giovannantonio LG, et al. 1050 Identification of sixteen novel candidate genes for late onset Parkinson's disease. Mol 1051 Neurodegener. 2021 Jun 21;16(1):35. 1052 70. Salem M, Ammitzboell M, Nys K, Seidelin JB, Nielsen OH. ATG16L1: A multifunctional 1053 susceptibility factor in Crohn disease. Autophagy. 2015 Apr 23;11(4):585–94. 1054 71. Hansson O, Kumar A, Janelidze S, Stomrud E, Insel PS, Blennow K, et al. The genetic 1055 regulation of protein expression in cerebrospinal fluid. EMBO Mol Med. 2023 Jan 1056 11;15(1):e16359. 1057 72. Cali E, Dominik N, Manole A, Houlden H. Riboflavin Transporter Deficiency. In: Adam 1058 MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, Gripp KW, et al., editors. 1059 GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 1060 2023 Jul 31]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK299312/ 1061 73. Novikova G, Kapoor M, Tcw J, Abud EM, Efthymiou AG, Chen SX, et al. Integration of 1062 Alzheimer's disease genetics and myeloid genomics identifies disease risk regulatory 1063 elements and genes. Nat Commun. 2021 Mar 12;12(1):1610. 1064 74. Allan CM, Walker D, Segrest JP, Taylor JM. Identification and characterization of a new 1065 human gene (APOC4) in the apolipoprotein E, C-I, and C-II gene locus. Genomics. 1995 1066 Jul 20;28(2):291-300. 1067 75. Wang P, Luo M, Zhou W, Jin X, Xu Z, Yan S, et al. Global Characterization of Peripheral B 1068 Cells in Parkinson's Disease by Single-Cell RNA and BCR Sequencing. Front Immunol. 1069 2022;13:814239. 1070 76. Lp Y, Mj S. The cryptic HLA-DQA2 ("DX alpha") gene is expressed in human B cell lines. 1071 Journal of immunology (Baltimore, Md : 1950) [Internet]. 1991 Dec 15 [cited 2023 Aug 1072 4];147(12). Available from: https://pubmed.ncbi.nlm.nih.gov/1753107/ 1073 77. Li GJ, Yang QH, Yang GK, Yang G, Hou Y, Hou LJ, et al. MiR-125b and SATB1-AS1 1074 might be shear stress-mediated therapeutic targets. Gene. 2023 Mar 20;857:147181. 1075 78. Naguib A, Sandmann T, Yi F, Watts RJ, Lewcock JW, Dowdle WE. SUPT4H1 Depletion 1076 Leads to a Global Reduction in RNA. Cell Rep. 2019 Jan 2;26(1):45-53.e4. 1077 79. Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol. 2019 1078 Aug;266(8):2075-86. 1079 80. Ballasch I, García-García E, Vila C, Pérez-González A, Sancho-Balsells A, Fernández J, et 1080 al. Ikzf1 as a novel regulator of microglial homeostasis in inflammation and 1081 neurodegeneration. Brain Behav Immun. 2023 Mar;109:144-61.

- 1082 81. Schutte B, Henfling M, Ramaekers FCS. DEDD association with cytokeratin filaments
 1083 correlates with sensitivity to apoptosis. Apoptosis. 2006 Sep;11(9):1561–72.
- 1084 82. Dahal A, Hinton SD. Antagonistic roles for STYX pseudophosphatases in neurite outgrowth.
 1085 Biochem Soc Trans. 2017 Apr 15;45(2):381–7.
- 83. Burgaletto C, Munafò A, Di Benedetto G, De Francisci C, Caraci F, Di Mauro R, et al. The
 immune system on the TRAIL of Alzheimer's disease. Journal of Neuroinflammation. 2020
 Oct 13;17(1):298.
- 1089 84. Traylor M, Persyn E, Tomppo L, Klasson S, Abedi V, Bakker MK, et al. Genetic basis of 1090 lacunar stroke: a pooled analysis of individual patient data and genome-wide association 1091 studies. Lancet Neurol. 2021 May;20(5):351–61.
- 1092 85. Chen K, Zhu L, Guo L, Pan YB, Feng DF. Maf1 regulates dendritic morphogenesis and
 1093 influences learning and memory. Cell Death Dis. 2020 Jul 30;11(7):606.
- 1094 86. Kumar AA, Yeo N, Whittaker M, Attra P, Barrick TR, Bridges LR, et al. Vascular Collagen
 1095 Type-IV in Hypertension and Cerebral Small Vessel Disease. Stroke. 2022
 1096 Dec;53(12):3696–705.
- 1097 87. Miners S, van Helmond Z, Barker R, Passmore PA, Johnston JA, Todd S, et al. Genetic
 1098 variation in MME in relation to neprilysin protein and enzyme activity, Aβ levels, and
 1099 Alzheimer's disease risk. Int J Mol Epidemiol Genet. 2012;3(1):30–8.
- 1100 88. Chen G, Li L, Tao H. Bioinformatics Identification of Ferroptosis-Related Biomarkers and
 1101 Therapeutic Compounds in Ischemic Stroke. Front Neurol. 2021;12:745240.
- 89. Pan Y, Fu Y, Baird PN, Guymer RH, Das T, Iwata T. Exploring the contribution of ARMS2
 and HTRA1 genetic risk factors in age-related macular degeneration. Prog Retin Eye Res.
 2022 Dec 27;101159.
- 90. Thee EF, Colijn JM, Cougnard-Grégoire A, Meester-Smoor MA, Verzijden T, Hoyng CB, et
 al. The Phenotypic Course of Age-Related Macular Degeneration for ARMS2/HTRA1: The
 EYE-RISK Consortium. Ophthalmology. 2022 Jul;129(7):752–64.
- 1108 91. Gatta LB, Vitali M, Zanola A, Venturelli E, Fenoglio C, Galimberti D, et al. Polymorphisms
 1109 in the LOC387715/ARMS2 putative gene and the risk for Alzheimer's disease. Dement
 1110 Geriatr Cogn Disord. 2008;26(2):169–74.
- 92. Wang P, Qin W, Wang P, Huang Y, Liu Y, Zhang R, et al. Genomic Variants in NEURL,
 GJA1 and CUX2 Significantly Increase Genetic Susceptibility to Atrial Fibrillation. Sci
 Rep. 2018 Feb 19;8(1):3297.
- 1114 93. Li RG, Xu YJ, Ye WG, Li YJ, Chen H, Qiu XB, et al. Connexin45 (GJC1) loss-of-function
 1115 mutation contributes to familial atrial fibrillation and conduction disease. Heart Rhythm.
 1116 2021 May;18(5):684–93.

- 1117 94. Zhu C, Xiao F, Lin W. EFTUD2 on innate immunity. Oncotarget. 2015 Oct 20;6(32):32313–
 1118 4.
- 95. Abo Elwafa R, Gamaleldin M, Ghallab O. The clinical and prognostic significance of FIS1,
 SPI1, PDCD7 and Ang2 expression levels in acute myeloid leukemia. Cancer Genet. 2019
 Apr;233–234:84–95.
- 96. Vadhvani M, Schwedhelm-Domeyer N, Mukherjee C, Stegmüller J. The centrosomal E3
 ubiquitin ligase FBXO31-SCF regulates neuronal morphogenesis and migration. PLoS One.
 2013;8(2):e57530.
- 1125 97. Serpeloni F, Nätt D, Assis SG de, Wieling E, Elbert T. Experiencing community and
 1126 domestic violence is associated with epigenetic changes in DNA methylation of BDNF and
 1127 CLPX in adolescents. Psychophysiology. 2020;57(1):e13382.
- 1128 98. ZSCAN29 zinc finger and SCAN domain containing 29 [Homo sapiens (human)] Gene 1129 NCBI [Internet]. [cited 2023 Aug 1]. Available from:
- 1130 https://www.ncbi.nlm.nih.gov/gene/146050#summary
- 1131 99. Baker TA, Sauer RT. ClpXP, an ATP-powered unfolding and protein-degradation machine.
 1132 Biochimica et Biophysica Acta (BBA) Molecular Cell Research. 2012 Jan 1;1823(1):15–
 1133 28.
- 1134 100. Thomas T, Perdue MV, Khalaf S, Landi N, Hoeft F, Pugh K, et al. Neuroimaging genetic
 1135 associations between SEMA6D, brain structure, and reading skills. J Clin Exp
 1136 Neuropsychol. 2021 Apr;43(3):276–89.
- 101. Perdue MV, Mascheretti S, Kornilov SA, Jasińska KK, Ryherd K, Einar Mencl W, et al.
 Common variation within the SETBP1 gene is associated with reading-related skills and
 patterns of functional neural activation. Neuropsychologia. 2019 Jul;130:44–51.
- 1140 102. Ziegler GC, Ehlis AC, Weber H, Vitale MR, Zöller JEM, Ku HP, et al. A Common CDH13
 1141 Variant Is Associated with Low Agreeableness and Neural Responses to Working Memory
 1142 Tasks in ADHD. Genes. 2021 Sep;12(9):1356.
- 1143 103. Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al.
 1144 Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature.
 1145 2022 Apr;604(7906):502–8.
- 104. Beeri MS, Lin HM, Sano M, Ravona-Springer R, Liu X, Bendlin BB, et al. Association of
 the Haptoglobin Gene Polymorphism With Cognitive Function and Decline in Elderly
 African American Adults With Type 2 Diabetes: Findings From the Action to Control
 Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Study. JAMA
 Netw Open. 2018 Nov 2;1(7):e184458.
- 1151 105. Kikuchi M, Yamada K, Toyota T, Yoshikawa T. C18orf1 located on chromosome 18p11.2
 1152 may confer susceptibility to schizophrenia. J Med Dent Sci. 2003 Sep;50(3):225–9.

- 1153 106. Zhang Z, Shang J, Dai Z, Yao Y, Shi Y, Zhong D, et al. Transmembrane Protein 170B is a
 1154 Prognostic Biomarker and Associated With Immune Infiltrates in Pancreatic
 1155 Adenocarcinoma. Front Genet. 2022;13:848391.
- 107. Ge Y, Grossman RI, Babb JS, Rabin ML, Mannon LJ, Kolson DL. Age-Related Total Gray
 Matter and White Matter Changes in Normal Adult Brain. Part I: Volumetric MR Imaging
 Analysis. American Journal of Neuroradiology. 2002 Sep 1;23(8):1327–33.
- 108. Davies G, Armstrong N, Bis JC, Bressler J, Chouraki V, Giddaluru S, et al. Genetic
 contributions to variation in general cognitive function: a meta-analysis of genome-wide
 association studies in the CHARGE consortium (N=53 949). Mol Psychiatry. 2015
 Feb;20(2):183–92.
- 109. Dumitrescu L, Mahoney ER, Mukherjee S, Lee ML, Bush WS, Engelman CD, et al.
 Genetic variants and functional pathways associated with resilience to Alzheimer's disease.
 Brain. 2020 Aug 25;143(8):2561–75.
- 110. Fridman AL, Tainsky MA. Critical pathways in cellular senescence and immortalization
 revealed by gene expression profiling. Oncogene. 2008 Oct;27(46):5975–87.
- 1168 111. Wainberg M, Sinnott-Armstrong N, Mancuso N, Barbeira AN, Knowles DA, Golan D, et
 al. Opportunities and challenges for transcriptome-wide association studies. Nat Genet.
 2019 Apr;51(4):592–9.
- 1171 112. Wu C, Pan W. A powerful fine-mapping method for transcriptome-wide association
 1172 studies. Hum Genet. 2020 Feb;139(2):199–213.
- 1173